Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Career Changes Are Challenging, but Hold On to Hope
    nursing professional development
    Career Changes Are Challenging, but Hold On to Hope
    June 04, 2021
    Mentors Changed My Career at Every Stage, From New Grad to Leader
    nursing professional development
    Mentors Changed My Career at Every Stage, From New Grad to Leader
    May 28, 2021
    The COVID-19 Pandemic Fast-Tracked Our Growth as Nurses
    COVID-19
    The COVID-19 Pandemic Fast-Tracked Our Growth as Nurses
    May 21, 2021
    When Everything Still Isn't Enough
    Advance care planning
    When Everything Still Isn't Enough
    April 30, 2021
    The Case of the Cord Blood Match
    Clinical practice
    The Case of the Cord Blood Match
    March 26, 2021
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    Oncology Drug Reference Sheet: Relugolix
    Clinical practice

    Oncology Drug Reference Sheet: Relugolix

    On December 18, 2020, the U.S. Food and Drug Administration approved relugolix (OrgovyxTM) as the first oral hormone therapy for use in adult patients with advanced prostate cancer. 

    April 27, 2021
    Be Alert for Axillary Adenopathy After COVID-19 Vaccination
    COVID-19

    Be Alert for Axillary Adenopathy After COVID-19 Vaccination

    Nearly 60 million people in the United States and almost 200 million around the world have received the COVID-19 coronavirus vaccine as of mid-February 2021, and the numbers will continue to grow as more doses come to market and other manufacturers’ versions receive emergency use authorizations. As more people get vaccinated, some of the expected side effects are being observed in clinical practice and have implications for cancer care. 

    February 19, 2021
    Oncology Drug Reference Sheet: Tafasitamab-Cxix
    Oncology drug research

    Oncology Drug Reference Sheet: Tafasitamab-Cxix

    Tafasitamab-cxix (Monjuvi®) received accelerated approval from the U.S. Food and Drug Administration in July 2020 in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma.

    January 26, 2021
    COVID-19 Drug Reference Sheet: Bamlanivimab
    COVID-19

    COVID-19 Drug Reference Sheet: Bamlanivimab and Etesevimab

    On November 9, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for bamlanivimab, an unapproved agent, to treat mild to moderate cases of the COVID-19 coronavirus. In April 2021, FDA revoked the EUA for bamlanivimab as single-agent therapy for COVID-19. As new variants emerged, data indicated that when administered alone, bamlanivimab’s benefits no longer outweighed its risks. It issued a new EUA for bamlaniviamab when administered in combination with etesevimab.

    November 20, 2020
    Oncology Drug Reference Sheet: Lurbinectedin
    Clinical practice

    Oncology Drug Reference Sheet: Lurbinectedin

    In June 2020, the U.S. Food and Drug Administration granted accelerated approval to lurbinectedin (ZepzelcaTM) for adults with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. The approval adds a second choice for patients who experience treatment-resistant SCLC progression, who previously had only topotecan as an option.

    October 20, 2020
    Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv
    U.S. Food and Drug Administration (FDA)

    Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv

    Enfortumab vedotin-ejfv (Padcev™) was granted accelerated approval in December 2019 for adults with locally advanced or metastatic urothelial cancer who previously received an immune checkpoint inhibitor (PD-1 or PD-L1 inhibitor) and platinum-containing therapy.

    July 28, 2020
    A Perspective on COVID-19 for New and Student Nurses
    COVID-19

    A Perspective on COVID-19 for New and Student Nurses

    COVID-19 coronavirus’s ripple effects extend so far beyond health and health care. Life in the United States doesn’t look the same as it did a few months ago. We’re all affected in some way, but senior nursing students have a distinct set of circumstances related to the pandemic.

    May 01, 2020
    Oncology Drug Reference Sheet: Tocilizumab (Actemra®)
    COVID-19

    Oncology Drug Reference Sheet: Tocilizumab

    Tocilizumab was approved in August 2017 for the treatment of chimeric antigen receptor T cell–induced cytokine release syndrome. In March 2020, the U.S. Food and Drug Administration approved a randomized, double-blind, placebo-controlled, phase III clinical trial to assess the safety and efficacy of tocilizumab plus standard of care in patients hospitalized with severe COVID-19 pneumonia.

    April 14, 2020
    Emotional Coping Strategies for COVID-19
    Clinical practice

    Emotional Coping Strategies for COVID-19

    The COVID-19 novel coronavirus pandemic is turning the world, inside and outside of the hospital, upside down. Not only are oncology nurses seeing high demands at work, but changes and restrictions are being instated at home as well.

    March 16, 2020
    COVID-19 Fact Sheet and Implications for Patients With Cancer
    Clinical practice

    COVID-19 Fact Sheet and Implications for Patients With Cancer

    COVID-19 is a novel coronavirus (a large family of viruses that can cause cold-like illnesses) first identified in Wuhan, China, in December 2019. It is a respiratory illness and can be spread from person to person, possibly through respiratory droplets during close contact. The first case of COVID-19 in the United States was reported on January 21, 2020.

    March 04, 2020
    Oncology Drug Reference Sheet: Niraparib
    Treatments

    Oncology Drug Reference Sheet: Niraparib

    Niraparib was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer. 

    February 25, 2020
    Oncology Drug Reference Sheet: Radium 223 Dichloride
    Treatments

    Oncology Drug Reference Sheet: Radium 223 Dichloride

    Radium 223 dichloride (Xofigo®) is an alpha particle-emitting radioactive therapeutic agent approved by the U.S. Food and Drug Administration in 2013 for castrate-resistant prostate cancer.

    December 24, 2019
    Beta Data Browser Puts Precision Medicine Cohort at Researchers’ Fingertips
    Oncology nurse scientist

    Beta Data Browser Puts Precision Medicine Cohort at Researchers’ Fingertips

    The future of cancer care is here: precision medicine has led to many of today’s newest cancer treatments and has made incredible progress since former President Barak Obama first announced the U.S. Precision Medicine Initiative (PMI) in 2015.

    June 27, 2019
    Combination Trastuzumab and Hyaluronidase-Oysk
    Treatments

    Oncology Drug Reference Sheet: Combination Trastuzumab and Hyaluronidase-Oysk

    A new product that combines trastuzumab and hyaluronidase (Herceptin Hylecta™) received U.S. Food and Drug Administration approval in February 2019 for the treatment of HER2-overexpressing breast cancer. The approval was based on the results of two randomized trials: HannaH and SafeHER. 

    June 18, 2019
    Which Ambulatory Infusion Pump Is Best for 5-FU?
    Treatments

    Which Ambulatory Infusion Pump Is Best for 5-FU?

    Because of its long infusion time over 46–48 hours, 5-fluorouracil (5-FU) is usually administered with an ambulatory infusion pump in the outpatient setting. However, two types of pumps exist. On one side of the spectrum is the elastomeric pump: small, compact, but gets the job done. On the other is the electronic pump: bigger, flashy, with lots of bells and whistles (literally). Here are the advantages and disadvantages of each.

    April 18, 2019
    Study Finds Three Priority Steps to Improve Cancer Survivorship
    Survivorship

    Study Finds Three Priority Steps to Improve Cancer Survivorship

    Healthcare providers need to address three priority areas to improve outcomes for cancer survivors and support caregivers for patients with cancer, according to findings from an evidence review published in CA: A Cancer Journal for Clinicians.

    January 23, 2019
    Oncology Drug Reference Sheet: Lutetium Lu 177 Dototate
    Treatments

    Oncology Drug Reference Sheet: Lutetium Lu 177 Dotatate

    Lutetium Lu 177 dototate (Lutathera®) was approved in January 2018 by the U.S. Food and Drug Administration to treat a specific group of neuroendocrine tumors (NETs) in the gastrointestinal tract. NETs are rare, and the tumors produce hormone-like substances in response to signals from the nervous system.

    January 23, 2019
    What APRNs Need to Know About Right to Try
    Advanced practice nursing (APN)

    What APRNs Need to Know About Right to Try

    The Right-to-Try law, which has been in effect since May 2018, may have a misleading name, given that it doesn’t require drug manufacturers to grant access to experimental treatments that have passed phase I trials to any patient who seeks it. Rather, the law grants terminally ill patients the “right to ask” the drug company directly, but the request can be denied for several reasons (e.g., limited supply, expense).

    October 16, 2018
    TNM Gets an Upgrade in Eighth Edition Staging Guidelines
    Clinical practice guidelines

    TNM Gets an Upgrade in Eighth Edition Staging Guidelines

    Nearly a century ago, cancer staging was a simple categorization of disease as either local, regional, or distant. Then in the 1940s, a French surgeon developed the concept for a staging system that uses the size of the primary tumor (T), its lymphatic involvement (N), and the presence of metastases (M) to stage a patient’s cancer based on the anatomic extent of the disease at the time of diagnosis.

    August 09, 2018

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap

  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲